Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

Atomoxetine in children with attention-deficit hyperactivity disorder with prior stimulant therapy: a prospective open-label study.

Hammerness P, Doyle R, Kotarski M, Georgiopoulos A, Joshi G, Zeitlin S, Biederman J.

Eur Child Adolesc Psychiatry. 2009 Aug;18(8):493-8. doi: 10.1007/s00787-009-0017-8. Epub 2009 Apr 18.

PMID:
19377865
2.

[Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].

Purper-Ouakil D, Fourneret P, Wohl M, Rénéric JP.

Encephale. 2005 May-Jun;31(3):337-48. Review. French.

PMID:
16142049
3.

Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.

Garnock-Jones KP, Keating GM.

Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. Review.

PMID:
19445548
4.

Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.

Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.

Clin Ther. 2007 Jun;29(6):1168-77.

PMID:
17692731
5.

Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.

Spencer T, Heiligenstein JH, Biederman J, Faries DE, Kratochvil CJ, Conners CK, Potter WZ.

J Clin Psychiatry. 2002 Dec;63(12):1140-7.

PMID:
12523874
6.

Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.

Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Saylor KE, Sutton VK, Gonzales J, Malcolm SK, Schuh KJ, Allen AJ.

Pediatrics. 2004 Jul;114(1):e1-8.

PMID:
15231966
7.

Effects of atomoxetine on attention-deficit/hyperactivity disorder in clinical pediatric treatment settings: a naturalistic study.

Bakken RJ, Paczkowski M, Kramer HP, Axelson AA, Williams DW, Malcolm SK, Sumner CR, Kelsey DK.

Curr Med Res Opin. 2008 Feb;24(2):449-60. doi: 10.1185/030079908X253627 .

PMID:
18179733
8.

Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in stimulant-naïve Swedish children and adolescents.

Svanborg P, Thernlund G, Gustafsson PA, Hägglöf B, Poole L, Kadesjö B.

Eur Child Adolesc Psychiatry. 2009 Apr;18(4):240-9. doi: 10.1007/s00787-008-0725-5. Epub 2009 Jan 20.

PMID:
19156355
9.

Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.

Dell'Agnello G, Maschietto D, Bravaccio C, Calamoneri F, Masi G, Curatolo P, Besana D, Mancini F, Rossi A, Poole L, Escobar R, Zuddas A; LYCY Study Group.

Eur Neuropsychopharmacol. 2009 Nov;19(11):822-34. doi: 10.1016/j.euroneuro.2009.07.008. Epub 2009 Aug 28.

PMID:
19716683
10.

Open-label trial of atomoxetine hydrochloride in adults with ADHD.

Johnson M, Cederlund M, Råstam M, Areskoug B, Gillberg C.

J Atten Disord. 2010 Mar;13(5):539-45. doi: 10.1177/1087054709332372. Epub 2009 May 20.

PMID:
19458384
11.

Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study.

Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, Spencer T; Atomoxetine ADHD Study Group.

Pediatrics. 2001 Nov;108(5):E83.

PMID:
11694667
12.

Atomoxetine in the treatment of adults with subthreshold and/or late onset attention-deficit hyperactivity disorder-not otherwise specified (ADHD-NOS): a prospective open-label 6-week study.

Surman C, Hammerness P, Petty C, Doyle R, Chu N, Gebhard N, Williams C, Biederman J.

CNS Neurosci Ther. 2010 Spring;16(1):6-12. doi: 10.1111/j.1755-5949.2009.00124.x.

PMID:
20070786
13.

Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis.

Cheng JY, Chen RY, Ko JS, Ng EM.

Psychopharmacology (Berl). 2007 Oct;194(2):197-209. Epub 2007 Jun 16.

PMID:
17572882
14.

Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders.

Allen AJ, Kurlan RM, Gilbert DL, Coffey BJ, Linder SL, Lewis DW, Winner PK, Dunn DW, Dure LS, Sallee FR, Milton DR, Mintz MI, Ricardi RK, Erenberg G, Layton LL, Feldman PD, Kelsey DK, Spencer TJ.

Neurology. 2005 Dec 27;65(12):1941-9.

PMID:
16380617
15.

Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.

Bangs ME, Hazell P, Danckaerts M, Hoare P, Coghill DR, Wehmeier PM, Williams DW, Moore RJ, Levine L; Atomoxetine ADHD/ODD Study Group.

Pediatrics. 2008 Feb;121(2):e314-20. doi: 10.1542/peds.2006-1880. Erratum in: Pediatrics.2008 Jul;122(1): 227.

PMID:
18245404
16.

Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial.

Adler LA, Spencer T, Brown TE, Holdnack J, Saylor K, Schuh K, Trzepacz PT, Williams DW, Kelsey D.

J Clin Psychopharmacol. 2009 Feb;29(1):44-50. doi: 10.1097/JCP.0b013e318192e4a0.

PMID:
19142107
17.

A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD).

Prasad S, Harpin V, Poole L, Zeitlin H, Jamdar S, Puvanendran K; SUNBEAM Study Group.

Curr Med Res Opin. 2007 Feb;23(2):379-94.

PMID:
17288692
18.

Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: a 6-week, randomized, placebo-controlled, double-blind trial in Russia.

Martenyi F, Zavadenko NN, Jarkova NB, Yarosh AA, Soldatenkova VO, Bardenstein LM, Kozlova IA, Neznanov NG, Maslova OI, Petrukhin AS, Sukchotina NK, Zykov VP.

Eur Child Adolesc Psychiatry. 2010 Jan;19(1):57-66. doi: 10.1007/s00787-009-0042-7. Epub 2009 Jul 1.

PMID:
19568826
19.

Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study.

Kemner JE, Starr HL, Ciccone PE, Hooper-Wood CG, Crockett RS.

Adv Ther. 2005 Sep-Oct;22(5):498-512.

PMID:
16418159
20.

Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder.

Biederman J, Heiligenstein JH, Faries DE, Galil N, Dittmann R, Emslie GJ, Kratochvil CJ, Laws HF, Schuh KJ; Atomoxetine ADHD Study Group.

Pediatrics. 2002 Dec;110(6):e75.

PMID:
12456942

Supplemental Content

Support Center